Publications by authors named "Koffi D Adoubryn"
Meta-Analysis of Data from Four Clinical Trials in the Ivory Coast Assessing the Efficacy of Two Artemisinin-Based Combination Therapies (Artesunate-Amodiaquine and Artemether-Lumefantrine) between 2009 and 2016.
Trop Med Infect Dis
December 2023
Article Synopsis
- Artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) are the first-line treatments for uncomplicated malaria in the Ivory Coast, with various studies examining their efficacy.
- This meta-analysis aimed to assess malaria treatment failures in randomized control trials comparing AL and ASAQ between 2009 and 2016, utilizing data from four multicenter studies.
- Results indicated high clinical and parasitological responses above 95% for both drug combinations, but a higher recurrence of infection was observed in the AL group compared to ASAQ, with most treatment failures classified as new infections after molecular testing.
Introduction: Malaria serology test seems to have attracted very little interest in endemic countries such as Ivory Coast. However, this examination has been regularly performed in the parasitology laboratory at the Training and Research Unit of Medical Sciences in Abidjan. Our study aimed to highlight the contribution of malaria serology test in our endemic country context.
View Article and Find Full Text PDFMalaria and HIV are the most important infections in subSaharan Africa, in terms of the morbidity and mortality they cause. Current data suggest a possible interaction between the two diseases. Cellular immunodeficiency due to HIV infection might increase the frequency and severity of malaria, as local populations in endemic areas become less resistant.
View Article and Find Full Text PDFBackground: Paragonimiasis is a neglected tropical disease caused by an infection with lung flukes that is transmitted through the consumption of undercooked crabs. The disease is often confused with tuberculosis. Paragonimiasis is thought to be endemic in south-western Côte d'Ivoire.
View Article and Find Full Text PDFBackground: Morbidity control of schistosomiasis relies on a single drug, praziquantel. The antimalarial drug mefloquine possesses interesting antischistosomal properties, yet no clinical studies have been performed.
Methods: We conducted a randomized, exploratory open-label trial to assess the efficacy and safety of mefloquine (25 mg/kg), artesunate (3 doses of 4 mg/kg), mefloquine-artesunate (3 doses of 100 mg artesunate plus 250 mg mefloquine), and praziquantel (40 mg/kg) against Schistosoma haematobium.